Emcure Q1 FY27: International momentum lifts growth as domestic stabilises

Emcure Pharmaceuticals opened FY27 with a strong quarter, supported by broad-based geographic execution. In Q1 FY27, revenue from operations rose 22.8 percent year on year to INR 2,580.4 crore. Profitability also improved, with EBITDA up 25.8 percent to INR 508.0 crore and EBITDA margin expanding 50 basis points to 19.7 percent. PAT grew faster at 36.2 percent to INR 292.5 crore and PAT margin improved 110 basis points to 11.3 percent.

A key theme of the quarter was the rising contribution of international markets. International revenue grew 34.2 percent year on year to INR 1,485.1 crore and contributed 58 percent of the quarterly revenue mix. Domestic revenue grew 10.2 percent to INR 1,095.3 crore, with management describing the growth as normalised and not driven by channel filling.

International business leads with Europe and RoW strength

International performance was strong across Europe, Canada and Rest of World (RoW). Europe revenue increased to INR 536.7 crore, supported by steady base business execution and a rising contribution from Liposomal Amphotericin B. Canada revenue grew to INR 426.6 crore, driven by market share gains and new launches, including one product approval and two launches during the quarter.

RoW revenue reached INR 521.8 crore, with management attributing performance to a strong order book in the ARV segment and continued scaling of the non-ARV portfolio. In the Q&A, management indicated that roughly two-thirds of RoW revenue in this quarter was ARV, though it expects the full-year ARV contribution to be around 50 to 55 percent.

Management also quantified the currency tailwind, stating that the forex impact was about 6 to 7 percent at the overall company level, and about 12 to 13 percent for international markets.

Domestic business: steady quarter, with acceleration expected

In India, the company’s domestic business delivered INR 1,095.3 crore in Q1 FY27. Management highlighted growth across CNS, women’s health and cardio-metabolics, and cited brands such as Tenectase, Orofer XT, Orofer FCM and Metpure. The quarter also reflected a stabilising trend in Zuventus after a period of disruption.

On the conference call, management framed the Zuventus journey in three phases: stability, consolidation and acceleration. It stated that stability has returned, consolidation is largely complete, and the organisation is moving toward acceleration. It expects domestic growth to be more in line with the industry from Q2 and to outperform the industry in the second half of FY27.

A useful data point from the Q&A was the split between reported domestic growth and organic growth. Management said that excluding the Sanofi OAD and Roche portfolio, domestic growth would have been about 6 to 7 percent in the quarter. This helps explain why reported growth was higher, aided by in-licensed portfolios.

The company continues to build the ramp-up of Poviztra, and management noted that a recent MASH indication could help expand engagement beyond traditional cardio-metabolic prescribers, though it also acknowledged that the broader market remains noisy and difficult to assess due to multiple brands and potential channel inventory.

Margin profile: EBITDA expands despite gross margin pressure

While EBITDA and PAT margins improved, gross margin declined year on year. Q1 FY27 gross profit margin stood at 58.4 percent versus 61.8 percent in Q1 FY26. Management attributed this largely to geography and business mix, noting that the outperformance in international markets can be associated with lower gross margin businesses but can still be EBITDA accretive due to operating leverage.

During the call, management guided that FY27 gross margins could trend around 59 percent given the likely mix, while reiterating its commitment to EBITDA margin expansion of 70 to 100 basis points.

R&D spending in Q1 FY27 was INR 90.4 crore, or 3.5 percent of revenue in the presentation, while management indicated that full-year R&D investment is expected to be in the 4 to 5 percent range.

Strategic updates: leadership depth and full control of Gennova

Beyond quarterly numbers, the company announced leadership and structural actions designed to support its five-year plan. Satish Mehta is expected to take over as Chairman in addition to Managing Director and CEO after the conclusion of the upcoming AGM. Samit Mehta has been appointed as COO with broader oversight of group R&D, operations and licensing.

A major group update was the acquisition of the remaining minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary. Management highlighted that this provides strategic control over its biologics and biosimilars platform and simplifies group structure across subsidiaries.

On business development and pipeline, management cited 15-plus product approvals across developed and emerging markets during Q1 FY27. It also highlighted a voluntary licensing agreement with MSD for almatavir, a once-monthly oral PrEP candidate currently in late-stage development, across 129 low and lower-middle income countries. Separately, it stated that ICMR licensed a novel anti-HPV candidate for Cervical Intraepithelial Neoplasia to Emcure under a technology transfer initiative.

Takeaways from Q1 FY27

Emcure’s Q1 FY27 performance underlined the strength of its diversified international platform and showed improving momentum in domestic operations as Zuventus normalises. The key variables to track through FY27 include the sustainability of international growth, the pace of domestic acceleration from Q2 onward, and the trajectory of gross margins given a more export-heavy mix.

Management reiterated low to mid-teen revenue growth for FY27 and 70 to 100 basis points EBITDA margin expansion. On leverage, it indicated net debt could rise in the near term due to acquisition-related payouts, while also stating an expectation to become net cash by end of FY28.